Clinical trial · Observational
Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
Development of a Clinical CEST MR Fingerprinting Method for Treatment Response Assessment in Brain Metastases
NCT05559853CI-TRIAL-00104832recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to develop and test a new magnetic resonance imaging (MRI) technique to see if it can be used to tell the difference between tumor growth from worsening of cancer and growth from the effects of treatment in participants who have brain tumors treated with radiation therapy called stereotactic radiosurgery (SRS).
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Metastases | — | UNRESOLVED | — |
| Brain Metastases, Adult | — | UNRESOLVED | — |
| Metastatic Brain Cancer | Malignant Brain Neoplasm | CURATED_BROADER | 0.78 |
| Metastatic Brain Tumor | Brain Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CEST-MRF | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Participants with Brain Metastases
- description
- Participants will have at least one untreated brain metastasis \> 1cm
- interventionNames
- Diagnostic Test: CEST-MRF
- label
- Healthy participants
- description
- Participants will have no known cancer diagnosis. Volunteers enrolled on this protocol may undergo multiple MRI examinations periodically for studies of reproducibility.
- interventionNames
- Diagnostic Test: CEST-MRF
Primary outcomes (1)
- measure
- Change of Rapid chemical exchange saturation transfer (CEST) imaging with magnetic resonance fingerprinting (MRF)/CEST-MRF parameters with and without motion
- timeFrame
- Up to 3 years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Healthy volunteers \[for Study Aim 1 (SA1) and Study Aim 2 (SA2)\] will be entered into the study if they meet the following criteria: * Age ≥ 18 years * Able to understand and give informed consent * No known cancer diagnosis Patients \[for Study Aim 1 (SA1)\] will be entered into the study if they meet the following criteria: * Age ≥ 18 years * Able to understand and give informed consent * At least one untreated brain metastasis \> 1cm (e.g., an enhancing lesion in the brain of a patient with known systemic cancer determined likely to represent metastasis by neuroradiologist) Patients \[for Study Aim 3 (SA3)\] will be entered into the study if they meet the following criteria: * Age ≥ 18 years * Able to understand and give informed consent * At least one untreated brain metastasis \> 1cm (e.g., an enhancing lesion in the brain of a patient with known systemic cancer determined likely to represent metastasis by neuroradiologist) * Planned SRS treatment Exclusion Criteria: Healthy volunteers (SA1 \& SA2) and patients (SA1 \& SA3) exclusion criteria: * Pregnant or breastfeeding women * Pre-existing medical conditions, including the likelihood of developing seizures or claustrophobic reactions, and any greater than normal potential for cardiac arrest * Age \< 18 years
References
Publications (0)
Data not yet available
No reference posted for this study.